BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2008

View Archived Issues

Recent patents cover new agents for endocrine disorders

Read More

Novel agents with possible use in obesity and other metabolic disorders described in recent patents

Read More

Radiosensitization seen with CEP-9722 in radioresistant glioblastoma xenografts

Read More

Eg5 kinesin inhibitor with cytotoxic activity discovered at ArQule

Read More

Destiny Pharma's XF-73 demonstrates activity against Gram-positive bacteria

Read More

Compugen discovers blood-based biomarker for diagnosis of lung cancer

Read More

DOR BioPharma initiates nonhuman primate efficacy studies of RiVax ricin toxin vaccine

Read More

Genentech and Biogen report negative results from phase II/III study of Rituxan in SLE

Read More

Insmed presents development update on Iplex and the follow-on biologics INS-19 and INS-20

Read More

Antisoma presents update on clinical development activities of its anticancer compounds

Read More

Alexza reports positive results from phase I clinical trial of Staccato for insomnia

Read More

Recent Pfizer and AstraZeneca patents disclose new treatment options for respiratory disorders

Read More

Safe delivery of gene therapy for the treatment of retinal dystrophy

Read More

Resolvin E1 analogues improve dry eye symptoms and may be suitable for other ocular disorders

Read More

AstraZeneca submits sNDA for Symbicort for COPD

Read More

MediQuest submits NDA to FDA to treat Raynaud's disease

Read More

SkyePharma presents positive phase III efficacy data for Flutiform

Read More

Regression of CNV with novel pan-tubulin inhibitor OC-10X

Read More

Merck Serono and ZymoGenetics initiate phase II clinical trial of atacicept in RMS

Read More

Partial efficacy of Merck & Co.'s novel SSTR2 antagonists in models of CNV

Read More

Lundbeck obtains expanded rights from Neurim to commercialize Circadin outside of E.U.

Read More

ISTA Pharmaceuticals presents new phase III clinical findings to support Bepreve NDA

Read More

FDA approves Advair 250/50 for reduction of exacerbations in COPD patients

Read More

Innocoll initiates dosing in phase II clinical trial of CollaRx gentamicin topical sponge

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing